Lotus Health Group 관리

관리 기준 확인 2/4

Lotus Health Group CEO는 Tao Li, Aug2022 에 임명되었습니다 의 임기는 2.25 년입니다. 는 CN¥ 1.49M 가치에 해당하는 회사 주식의 0.017% 직접 소유합니다. 1.49M. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 4 년입니다.

주요 정보

Tao Li

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	2.3yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

These 4 Measures Indicate That Lotus Health Group (SHSE:600186) Is Using Debt Reasonably Well

Oct 14

Lotus Health Group Company (SHSE:600186) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Oct 14

There's Reason For Concern Over Lotus Health Group Company's (SHSE:600186) Price

Aug 23

These 4 Measures Indicate That Lotus Health Group (SHSE:600186) Is Using Debt Reasonably Well

Jun 07

Lotus Health Group Company's (SHSE:600186) Business Is Trailing The Market But Its Shares Aren't

Apr 30

Here's Why Lotus Health Group (SHSE:600186) Has Caught The Eye Of Investors

Feb 27

CEO

Tao Li (52 yo)

2.3yrs

테뉴어

CN¥155,900

보상

Mr. Tao Li serves as Co-President of Lotus Health Group Company since August 10, 2022.

리더십 팀

이름	위치	테뉴어	보상	소유권
Tao Li	Co-President	2.3yrs	CN¥155.90k	0.017% CN¥ 1.5m
Xian Hui Luo	VP, Secretary & Director	4.5yrs	CN¥620.00k	0.014% CN¥ 1.2m
Jin Rui Wang	Assistant to the President	4.4yrs	CN¥480.00k	데이터 없음
Haifeng Li	Vice President	4.8yrs	CN¥525.00k	0.014% CN¥ 1.2m
Jiasheng Cao	President & Director	no data	데이터 없음	데이터 없음
Teng Yu	VP & Supervisor	2.4yrs	데이터 없음	데이터 없음
Songfeng Yang	Assistant to the President	3.2yrs	데이터 없음	0.011% CN¥ 995.6k

3.8yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: 600186 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xian Hui Luo	VP, Secretary & Director	6.5yrs	CN¥620.00k	0.014% CN¥ 1.2m
Jiasheng Cao	President & Director	3.1yrs	데이터 없음	데이터 없음
Teng Yu	VP & Supervisor	4.8yrs	데이터 없음	데이터 없음
Maoxin Chen	Independent Director	4.8yrs	CN¥100.00k	데이터 없음
He Jun Wang	Independent Director	4.8yrs	CN¥100.00k	데이터 없음
De Zhou Zheng	Director	4.8yrs	CN¥620.00k	0.014% CN¥ 1.2m
Yijun Wang	Independent Director	2.3yrs	CN¥40.00k	데이터 없음
Chen Yongjian	Director	4.8yrs	CN¥60.00k	데이터 없음
Jian Guo	Director	3.1yrs	CN¥620.00k	0.014% CN¥ 1.2m
Tongsen Deng	Director	3.1yrs	데이터 없음	데이터 없음
Liu Jun	Chairman of the Supervisory Board	3.3yrs	데이터 없음	데이터 없음
William Li	Vice Chairman	2.3yrs	CN¥139.80k	데이터 없음

4.0yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 이사회: 600186 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

Lotus Health Group 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Lotus Health Group Company, Annual General Meeting, May 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.036 (vs CN¥0.025 in 3Q 2023)

Lotus Health Group Company (SHSE:600186) announces an Equity Buyback for CNY 150 million worth of its shares.

These 4 Measures Indicate That Lotus Health Group (SHSE:600186) Is Using Debt Reasonably Well

Lotus Health Group Company (SHSE:600186) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected

Lotus Health Group Company to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 25%

Now 22% overvalued

Second quarter 2024 earnings released

There's Reason For Concern Over Lotus Health Group Company's (SHSE:600186) Price

Now 21% overvalued

Lotus Health Group Company to Report First Half, 2024 Results on Aug 31, 2024

These 4 Measures Indicate That Lotus Health Group (SHSE:600186) Is Using Debt Reasonably Well

Lotus Health Group Company, Annual General Meeting, May 21, 2024

Lotus Health Group Company's (SHSE:600186) Business Is Trailing The Market But Its Shares Aren't

Full year 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.03 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.03 in FY 2022)

Lotus Health Group Company to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Financial data availability

Here's Why Lotus Health Group (SHSE:600186) Has Caught The Eye Of Investors

Lotus Health Group Company to Report Fiscal Year 2023 Results on Apr 30, 2024

Lotus Health Group Company to Report Q3, 2023 Results on Oct 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.005 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.013 in 2Q 2021)

Lotus Health Group Company (SHSE:600186) announces an Equity Buyback for CNY 100 million worth of its shares.

Lotus Health Group Company (SHSE:600186) announces an Equity Buyback for CNY 100 million worth of its shares.

First quarter 2022 earnings released: EPS: CN¥0.008 (vs CN¥0.008 in 1Q 2021)

Less than half of directors are independent

Second quarter 2021 earnings released: EPS CN¥0.013 (vs CN¥0.014 in 2Q 2020)

Lotus Health Group Company announced that it has received CNY 993.545246 million in funding from a group of investors

First quarter 2021 earnings released: EPS CN¥0.008 (vs CN¥0.009 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.05 in FY 2019)

Lotus Health Group Company to Report Fiscal Year 2020 Results on Mar 31, 2021

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥0.05 in FY 2019)

New 90-day high: CN¥3.07

New 90-day high: CN¥2.99

Third quarter earnings released

Lotus Health Group Company to Report Q3, 2020 Results on Oct 31, 2020

New 90-day high - CN¥2.90

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령